Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Long-Term Open-Label Safety Study of Adjunctive Troriluzole in OCD
2024-512108-20-00Phase 3Completed
- Sponsor
- Pfizer
- Start
- Jul 2024
- Modality
- Orthosteric Ligands → Classical Binding Small Molecules → Small Molecules, Allosteric Modulators → Classical Binding Small Molecules → Small Molecules, Peptides
- Countries
- 5
01
Overview
Phase 3, open-label, single-arm trial of troriluzole in obsessive compulsive disorder (OCD), sponsored by Pfizer. Primary endpoint: Safety and tolerability of adjunctive Troriluzole. Started Jul 2024; status: completed.
02
Drugs
troriluzole
03
Conditions
obsessive compulsive disorder (OCD)
Beyond the preview
Go deeper on 2024-512108-20-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-512108-20-00.